GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

This 2017 *Frontiers in Pharmacology* paper from the Moscow-Tampere collaboration anchored by Myasoedov's group is one of the few Western-indexed mechanism papers on Selank with a full Western-journal peer-review record. The investigators examined 84 genes involved in GABAergic neurotransmission in human IMR-32 neuroblastoma cells, applying Selank, GABA, the atypical antipsychotic olanzapine, and combinations of the three. The headline finding has two parts: Selank alone produced no change in mRNA levels of any of the studied GABAergic genes, and Selank in combination with GABA suppressed the gene-expression changes that GABA produced when administered alone. When combined with olanzapine, Selank instead amplified the gene-expression alterations. The authors interpret the pattern as evidence that Selank does not directly modulate GABAergic gene expression but does modulate the response of those genes to other inputs — consistent with an allosteric or co-modulatory mechanism rather than a primary GABAergic ligand. This framing supports the broader hypothesis that Selank affects the interaction between GABA and GABA-A receptors rather than acting as a direct receptor agonist itself.

This is a cell-line gene-expression study, not a clinical trial. The IMR-32 neuroblastoma line is a useful model for GABAergic gene expression but does not capture the full neuronal complexity of in-vivo brain tissue under physiological conditions. The mechanistic interpretation — Selank as co-modulator — is consistent with the findings here but is not directly tested in the human clinical setting. The authors are part of the Russian research lineage that has produced most of the world's Selank literature; while the methodology in this Western-journal paper is rigorous, the broader Selank evidence base remains parallel to (rather than overlapping with) the FDA-grade clinical evidence required for psychiatric-drug approval in the U.S. or EU. Readers should treat the gene-expression findings as a real mechanistic clue without inferring that they translate directly to clinical anxiolytic efficacy.